Hrain Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2015-07-20
- Employees
- 101
- Market Cap
- -
- Website
- http://www.dashengbio.com
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Early Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06760260
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Early Phase 1
Recruiting
- Conditions
- Multiple MyelomaPlasma Cell Leukemia
- Interventions
- Drug: Human BCMA targeted CAR-NK cells injection
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06045091
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Early Phase 1
Recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT05651191
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Early Phase 1
Recruiting
- Conditions
- Central Nervous System Lymphoma
- Interventions
- Drug: Human CD19-CD22 Targeted T Cells Injection
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05651178
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Human BCMA Targeted T Cells Injection
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05594797
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2
Recruiting
- Conditions
- B-cell Non-Hodgkin's Lymphoma
- Interventions
- Drug: Human CD19Targeted T Cells Injection
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05436223
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Early Phase 1
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05302648
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
Phase 1
Not yet recruiting
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: Human CD19-CD22 Targeted T Cells Injection
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05223686
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Phase 1
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Human BCMA targeted T Cells Injection
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04003168
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
🇨🇳The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
🇨🇳Shanghai Changzheng Hospital, Shanghai, Shanghai, China
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Early Phase 1
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03943472
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath